Uniqure (QURE) Shares Up 5.9%

Uniqure NV (NASDAQ:QURE) shot up 5.9% during mid-day trading on Tuesday . The company traded as high as $18.85 and last traded at $18.20. 593,043 shares were traded during mid-day trading, an increase of 87% from the average session volume of 317,018 shares. The stock had previously closed at $17.19.

A number of brokerages recently issued reports on QURE. Evercore ISI began coverage on Uniqure in a research note on Tuesday, November 7th. They issued an “outperform” rating and a $22.00 price objective on the stock. Zacks Investment Research upgraded Uniqure from a “sell” rating to a “hold” rating and set a $21.00 price objective on the stock in a research note on Tuesday, October 24th. ValuEngine cut Uniqure from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. HC Wainwright began coverage on Uniqure in a research note on Friday, December 1st. They issued a “buy” rating and a $28.00 price objective on the stock. Finally, Oppenheimer restated a “hold” rating on shares of Uniqure in a research note on Friday, November 24th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. Uniqure currently has an average rating of “Hold” and an average price target of $19.29.

The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.64 and a current ratio of 3.64.

Several institutional investors and hedge funds have recently made changes to their positions in QURE. Mangrove Partners increased its position in shares of Uniqure by 167.4% during the third quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock valued at $1,024,000 after buying an additional 66,763 shares during the period. FMR LLC increased its position in shares of Uniqure by 4.1% during the second quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock valued at $9,656,000 after buying an additional 61,650 shares during the period. OxFORD Asset Management LLP bought a new stake in shares of Uniqure during the third quarter valued at about $399,000. Finally, JPMorgan Chase & Co. increased its position in shares of Uniqure by 33.5% during the second quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after buying an additional 14,659 shares during the period. Hedge funds and other institutional investors own 24.87% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/12/21/uniqure-qure-shares-up-5-9.html.

Uniqure Company Profile

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

What are top analysts saying about Uniqure? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Uniqure and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit